Sage Journals: Discover world-class research

Abstract

Background:

Immediate post-injection reactions were commonly observed in registrational trials of glatiramer acetate (GA) for the treatment of multiple sclerosis. Immediate post-injection reactions, characterized by a constellation of symptoms that may occur immediately after injection, can involve signs and symptoms that resemble those of anaphylaxis.

Objective:

The objective of this study is to describe cases of serious anaphylaxis that supported the postmarketing safety labeling change for GA in the United States.

Methods:

A review of the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) database and published medical literature was conducted.

Results:

We identified 82 cases of anaphylaxis with GA in FAERS and the medical literature. Six cases reported a fatal outcome (3 anaphylaxis, 3 sudden death). These cases reported anaphylaxis occurring in patients 1 week to 72 months following initiation of GA, including 19 cases that reported anaphylaxis more than 1 year following initiation of GA.

Conclusion:

As these reactions have implications for prescribing decisions and patient management, the FDA issued a labeling change notification to update the WARNINGS AND PRECAUTIONS section and add a BOXED WARNING to the United States prescribing information for GA. A Drug Safety Communication was also issued to inform the public about this update.

Keywords

Glatiramer acetate anaphylaxis multiple sclerosis

Get full access to this article

View all access options for this article.

References

Teva Neuroscience Inc. Copaxone (glatiramer acetate) prescribing information. Parsippany, NJ: Teva Neuroscience, Inc, 2023.

Arnon

Aharoni

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci USA 2004; 101(Suppl. 2): 14593–14598.

Webb

Teitelbaum

Arnon

, et al. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol 1973; 3(5): 279–286.

US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard, 2024. Available at: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard (accessed 13 March 2025).

MedDRA. MedDRA basics. Available at: https://www.meddra.org/basics (accessed 21 March 2025).

Code of Federal Regulations. 21 CFR 314.80—Postmarketing reporting of adverse drug experiences. 2025. Available at: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-B/section-314.80 (accessed 18 March 2025).

Simons

FER

Ardusso

LRF

Bilo

, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 2011; 4: 13–37.

Simons

FER

Ardusso

LRF

Bilo

, et al. 2012 update: World Allergy Organization (WAO) guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 2012; 12: 389–399.

Simons

Ardusso

Dimov

, et al. World Allergy Organization anaphylaxis guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol 2013; 162(3): 193–204.

10.

US Food and Drug Administration. Best practices in drug and biological product postmarket safety surveillance for FDA staff. 2024. Available at: https://www.fda.gov/media/130216/download?attachment (accessed 21 March 2025).

11.

Genentech Inc. Xolair (omalizumab) prescribing information. South San Francisco, CA: Genentech, Inc, 2024.

12.

Price

Hamilton

RG.

Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007; 28(3): 313–319.

13.

Rauschka

Farina

Sator

, et al. Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology 2005; 64(8): 1481–1482.

14.

Calogiuri

Muratore

Nettis

, et al. Immediate-type hypersensitivity reaction to mannitol as drug excipient (E421): A case report. Eur Ann Allergy Clin Immunol 2015; 47(3): 99–102.

15.

Hegde

Venkatesh

YP.

Anaphylaxis to excipient mannitol: Evidence for an immunoglobulin E-mediated mechanism. Clin Exp Allergy 2004; 34(10): 1602–1609.

16.

Broyles

Banerji

Barmettler

, et al. Practical guidance for the evaluation and management of drug hypersensitivity: Specific drugs. J Allergy Clin Immunol Pract 2020; 8(9S): S16–S116.

17.

Wöhrl

Felix

Wantke

, et al. Anaphylaxis to glatiramer acetate. Open Allergy J 2015; 8(1): 23–25.

18.

Cianferoni

Non-IgE-mediated anaphylaxis. J Allergy Clin Immunol 2021; 147(4): 1123–1131.

19.

Khan

Banerji

Blumenthal

, et al. Drug allergy: A 2022 practice parameter update. J Allergy Clin Immunol 2022; 150(6): 1333–1393.

20.

Menzin

Caon

Nichols

, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013; 19(1 SupplA): S24–40.

21.

Tremlett

Van der Mei

Pittas

, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: Contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008; 17(6): 565–576.

22.

Potter

Reyes

Naples

, et al. FDA adverse event reporting system (FAERS) essentials: A guide to understanding, applying, and interpreting adverse event data reported to FAERS. Clin Pharmacol Ther 2025; 118(3): 567–582.

23.

Bégaud

Martin

Haramburu

, et al. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002; 288: 1588.

24.

La Grenade

Graham

Nourjah

. Underreporting of hemorrhagic stroke associated with phenylpropanolamine. JAMA 2001; 286: 3081.

Anaphylaxis and glatiramer acetate

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References